All In Biotech

Free tool

FAERS Monitor: Symproic

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208854 or its brand name (Symproic, Naldemedine Tosylate). Reports on generic versions are filed under their own applications.

Reports

1,662

Serious

1,228

74% of reports

Hospitalization

698

Death reported

465

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea191
  • nausea132
  • constipation111
  • drug ineffective111
  • malignant neoplasm progression98
  • abdominal pain92
  • interstitial lung disease81
  • decreased appetite78
  • malaise69
  • anaemia65
  • pyrexia64
  • vomiting60
  • off label use55
  • hepatic function abnormal54
  • febrile neutropenia50

Reports by year received

View as table
YearReports
20131
20144
20152
201765
2018371
2019196
2020132
2021134
2022189
2023143
2024156
2025168
2026101

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,497 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
interstitial lung diseaseSignal8121.217.11,540
hepatic function abnormalSignal5418.314.1868
malignant neoplasm progressionSignal9812.110.0993
febrile neutropeniaSignal509.57.3375
constipationSignal1116.45.4510
abdominal painSignal925.04.1294
anaemiaSignal654.33.4164
decreased appetiteSignal784.33.4193
diarrhoeaSignal1913.73.3394
pyrexiaSignal642.31.849
nauseaSignal1322.11.879
malaise692.01.634
vomiting601.61.314
drug ineffective1111.10.90
off label use550.80.63

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.